A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have suggested that EGFR-TKI has limited potential as adjuvant therapy. On the contrary, based on subset ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibaki, Ryota, Akamatsu, Hiroaki, Kato, Terufumi, Nishino, Kazumi, Okada, Morihito, Mitsudomi, Tetsuya, Wakuda, Kazushige, Yoshimura, Kenichi, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy for lung cancer: progress, opportunities and challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841658/
https://www.ncbi.nlm.nih.gov/pubmed/33613698
http://dx.doi.org/10.1177/1758835920987647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841658/
https://www.ncbi.nlm.nih.gov/pubmed/33613698
http://dx.doi.org/10.1177/1758835920987647

Ejemplares similares